The issuance of this patent adds to the company's intellectual property portfolio with 11 issued U.S. patents and 34 foreign equivalents. The company's second technology, Switch-Blocker, can be used for the detection of important rare genetic events in cancer and drug resistance. The intellectual property underlying the Primer-Switch and the Switch-Blocker technologies is jointly owned by Aegea and Biocept.

Under Aegea and Biocept's cross licensing agreement relating to the Primer-Switch and Switch-Blocker intellectual property, Aegea has exclusive rights in the field of infectious disease, and Biocept has certain rights within the field of clinical oncology. Aegea is the sole owner of its nine other issued U.S. patents and their foreign equivalents.

The Primer-Switch technology is used for the detection of rare genetic events, and to enhance performance and specificity of polymerase chain reaction amplification reactions and next-generation sequencing, which are widely used in molecular diagnostic testing, including COVID-19 testing, and hereditary disease testing.